Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan

References

• Cowan A, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–1227. doi:10.1001/jamaoncol.2018.2128
   PubMed Web of Science ®Google Scholar
• Tang CH, Hou HA, Huang KC, et al. Treatment evolution and improved survival in multiple myeloma in Taiwan. Ann Hematol. 2020;99(2):321–330. doi:10.1007/s00277-019-03858-w
   PubMed Web of Science ®Google Scholar
• Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676–681. doi:10.1053/j.seminoncol.2016.11.004
   PubMed Web of Science ®Google Scholar
• Wang J, Lv C, Zhou M, et al. Second primary malignancy risk in multiple myeloma from 1975 to 2018. Cancers (Basel). 2022;14(19):4919. doi:10.3390/cancers14194919
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. Globocan 2020. Multiple myeloma [Internet]. [cited 2023 Mar 8]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/35-Multiple-myeloma-fact-sheet.pdf.
   Google Scholar
• Tang CH, Liu HY, Hou HA, et al. Epidemiology of multiple myeloma in Taiwan, a population based study. Cancer Epidemiol. 2018;55:136–141. doi:10.1016/j.canep.2018.06.003
   PubMed Web of Science ®Google Scholar
• Ministry of Health and Welfare Central Health Insurance Administration. Drug payment regulations [Internet]. [cited 2023 Apr 28]. Available from: https://www.nhi.gov.tw/Content_List.aspx?n = E70D4F1BD029DC37&topn = 3FC7D09599D25979.
   Google Scholar
• National Health Insurance Administration, Ministry of Health and Welfare. The latest version of drug payment regulations (take away the entire copy) - updated on 113.03.25 [Internet]. [cited 2024 Mar 31]. Available from: https://www.nhi.gov.tw/ch/cp-13108-67ddf-2508-1.html.
   Google Scholar
• Liu Y, Tang CH, Qiu H, et al. Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan. Sci Rep. 2021;11(1):1112. doi:10.1038/s41598-020-80607-4
   PubMed Web of Science ®Google Scholar
• Hung YC, Gau JP, Huang SY, et al. Pomalidomide and dexamethasone are effective in relapsed or refractory multiple myeloma in a real-life setting: a multicenter retrospective study in Taiwan. Front Oncol. 2021;11:695410. doi:10.3389/fonc.2021.695410
   PubMed Web of Science ®Google Scholar
• Fu WJ, Wang YF, Zhao HG, et al. Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial. BMC Cancer. 2022;22(1):722. doi:10.1186/s12885-022-09802-y
   PubMed Web of Science ®Google Scholar
• Taiwan Food and Drug Administration [Internet]. [cited 2023 Jul 11]. Available from: https://www.fda.gov.tw/TC/index.aspx.
   Google Scholar
• Chiu LJ, Kuo CY, Ma MC, et al. Real-world evidence of daratumumab-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a single-center experience in Taiwan focusing on efficacy. J Cancer Res Pract. 2023;10(1):19–23. doi:10.4103/ejcrp.eJCRP-D-22-00032
   Google Scholar
• Sunami K, Ikeda T, Huang SY, et al. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Clin Lymphoma Myeloma Leuk. 2022;22(8):e751–e761. doi:10.1016/j.clml.2022.04.005
   PubMed Web of Science ®Google Scholar
• Richardson PG, Perrot A, San-Miguel J, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022;23(3):416–427. doi:10.1016/S1470-2045(22)00019-5
   PubMed Web of Science ®Google Scholar
• Taiwan Food and Drug Administration. Assessment Report [Internet]. [cited 2023 Apr 19]. Available from: https://www.fda.gov.tw/tc/includes/GetFile.ashx?id = f637962576674226128&type = 2&cid = 41446.
   Google Scholar
• ClinicalTrials.gov. NCT02990338: Multinational clinical study comparing isatuximab, pomalidomide, and dexamethasone to pomalidomide and dexamethasone in refractory or relapsed and refractory multiple myeloma patients (ICARIA-MM) [Internet]. [cited 2023 Apr 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02990338.
   Google Scholar
• Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295–304. doi:10.2147/JMDH.S160029
   PubMed Web of Science ®Google Scholar
• Di Maio M, Perrone F, Conte P. Real-world evidence in oncology: opportunities and limitations. Oncologist. 2020;25(5):e746–e752. doi:10.1634/theoncologist.2019-0647
   PubMed Web of Science ®Google Scholar
• Liu WN, Chang CF, Chung CH, et al. Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: a nationwide population-based study and a single-institute analysis. PLoS One. 2019;14(9):e0222522.
   PubMed Web of Science ®Google Scholar
• Liu Y, Hou HA, Qiu H, et al. Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan. Sci Rep. 2020;10(1):14393. doi:10.1038/s41598-020-71243-z
   PubMed Web of Science ®Google Scholar
• Chen JH, Chung CH, Wang YC, et al. Prevalence and mortality-related factors of multiple myeloma in Taiwan. PLoS One. 2016;11(12):e0167227.
   PubMed Web of Science ®Google Scholar
• Kaweme NM, Changwe GJ, Zhou F. Approaches and challenges in the management of multiple myeloma in the very old: future treatment prospects. Front Med. 2021;8:612696. doi:10.3389/fmed.2021.612696
   Web of Science ®Google Scholar
• Fotiou D, Gavriatopoulou M, Terpos E, et al. Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma. Ther Adv Hematol. 2022;13:20406207221090090. doi:10.1177/20406207221090089
   Web of Science ®Google Scholar
• Szabo AG, Thorsen J, Iversen KF, et al. The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies. eJHaem [Internet]. 2023 Nov 24;4(4):1006–1012. Available from: https://onlinelibrary.wiley.com/doi/10.1002jha2.774
   PubMedGoogle Scholar
• Baldoni AdO, Chequer FMD, Ferraz ERA, et al. Elderly and drugs: risks and necessity of rational use. Brazilian J Pharm Sci. 2010;46(4):617–632. doi:10.1590/S1984-82502010000400003
   Web of Science ®Google Scholar
• Offidani M, Corvatta L, Gentili S. Triplet vs. doublet drug regimens for managing multiple myeloma. Expert Opin Pharmacother. 2018;19(2):137–149. doi:10.1080/14656566.2017.1418856
   PubMed Web of Science ®Google Scholar